NCT07502976 Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution for Androgenetic Alopecia
| NCT ID | NCT07502976 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kasr El Aini Hospital |
| Condition | Androgenic Alopecia |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-01-01 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Androgenetic alopecia is a common form of hair loss that can affect quality of life. This randomized controlled trial aims to evaluate the efficacy and safety of topical 2-Deoxy-D-ribose (2dDR) hydrogel compared with topical minoxidil 5% solution in the treatment of mild to moderate androgenetic alopecia in adults aged 18 to 50 years. Sixty participants will be randomized into 2 treatment groups. The 2dDR group will apply 1 gram of topical 2dDR hydrogel once daily to the affected scalp areas for 6 months. The minoxidil group will apply topical minoxidil 5% solution to the affected scalp areas for 6 months according to sex-specific dosing in the protocol. Participants will undergo clinical assessment, trichoscopic evaluation, and standardized scalp photography at baseline, Week 12, and Week 24. The study will also assess tissue vascular endothelial growth factor (VEGF) levels using scalp biopsy specimens obtained at baseline and after 3 months of treatment in both groups. Safety will be evaluated through adverse event monitoring and clinical scalp examination during follow-up visits.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 to 50 years. * Male and female patients with androgenetic alopecia. * Mild to moderate disease severity, defined as Hamilton-Norwood scale II to V in males and Ludwig scale I to II in females. * Ability and willingness to provide written informed consent. Exclusion Criteria: * Other types of hair loss, including inflammatory or scarring alopecia. * Psoriasis. * Inflammatory scalp dermatoses. * History of severe systemic disease, including renal, cardiovascular, or hepatic disease. * Chemotherapy during the last 5 years. * Pregnancy. * Lactation. * Bleeding disorders.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07502976 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Androgenic Alopecia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07502976 currently recruiting?
Yes, NCT07502976 is actively recruiting participants. Contact the research team at heba.a.abdelgayed@kasralainy.edu.eg for enrollment information.
Where is the NCT07502976 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07502976 clinical trial?
NCT07502976 is sponsored by Kasr El Aini Hospital. The trial plans to enroll 60 participants.